BridgeBio Pharma recently reported a strong and accelerating launch of its heart drug Attruby, with rapid growth in unique patient prescriptions and prescribers, supported by compelling clinical ...

Good afternoon, everyone, and thank you for joining BridgeBio Pharma's Second Quarter 2025 Earnings Call. With me today are Neil Kumar, our CEO; Matt Outten, our Chief Commercial Officer; and Tom ...

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

Pfizer’s recent positive data for atirmociclib, tilrekimig, Padcev, and the Lyme disease vaccine candidate highlight pipeline progress. See why PFE stock is a buy.

Adds Pfizer statement. BridgeBio (BBIO) fell 1.3% after originally gaining 11% as a court filing disclosed a settlement in a ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today upcoming presentations, ...

CM, often mistaken for other heart conditions, where earlier diagnosis and treatment may help improve outcomes 1. PALO ALTO, ...

Investing.com - Barclays reiterated an Overweight rating and $157.00 price target on BridgeBio Pharma (NASDAQ:BBIO). The firm estimates first-quarter U.S. Attruby revenue of $175 million versus ...

Investing.com - Mizuho reiterated an Outperform rating and $106.00 price target on BridgeBio Pharma stock (NASDAQ:BBIO) ahead of a patent trial involving Pfizer’s tafamidis. The stock currently trades ...